Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ARS Pharmaceuticals, Inc. - Common Stock
(NQ:
SPRY
)
11.65
+0.01 (+0.09%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ARS Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
ARS Pharma SPRY Q3 2025 Earnings Call Transcript
↗
November 10, 2025
ARS Pharma SPRY Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss
↗
November 10, 2025
ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion.
Via
Chartmill
Earnings Scheduled For November 10, 2025
↗
November 10, 2025
Via
Benzinga
Earnings Outlook For ARS Pharmaceuticals
↗
November 07, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 03, 2025
Via
Benzinga
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment
↗
September 23, 2025
ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns.
Via
Benzinga
Earnings Outlook For ARS Pharmaceuticals
↗
August 12, 2025
Via
Benzinga
ARS Pharmaceuticals's Earnings: A Preview
↗
May 13, 2025
Via
Benzinga
ARS Pharma Sales Jump 3,040% in Q2
↗
August 13, 2025
Via
The Motley Fool
ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists
↗
August 13, 2025
ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway.
Via
Chartmill
Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs
↗
June 12, 2025
Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
March 20, 2025
Via
Benzinga
Earnings Scheduled For November 13, 2024
↗
November 13, 2024
Via
Benzinga
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
↗
November 12, 2024
Via
Benzinga
Where ARS Pharmaceuticals Stands With Analysts
↗
October 08, 2024
Via
Benzinga
Analyst Ratings For ARS Pharmaceuticals
↗
September 09, 2024
Via
Benzinga
Earnings Scheduled For August 13, 2025
↗
August 13, 2025
Via
Benzinga
Earnings Scheduled For May 14, 2025
↗
May 14, 2025
Via
Benzinga
Which stocks are gapping on Thursday?
↗
March 20, 2025
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
↗
March 20, 2025
The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions.
Via
Investor's Business Daily
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
↗
March 20, 2025
Via
Benzinga
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment
↗
March 06, 2025
FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.
Via
Benzinga
Earnings Scheduled For March 20, 2025
↗
March 20, 2025
Via
Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
↗
January 17, 2025
Many stocks flashed buy signals as the major indexes rose to or above key levels.
Via
Investor's Business Daily
Topics
Economy
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
↗
January 13, 2025
Some companies saw their shares skyrocket on preliminary reports, but others took hits.
Via
Investor's Business Daily
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
↗
November 11, 2024
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it.
Via
Investor's Business Daily
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
↗
November 11, 2024
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.
Via
Benzinga
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
↗
August 23, 2024
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles.
Via
Benzinga
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
↗
August 20, 2024
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...
Via
Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
↗
August 20, 2024
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
